Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at The Cowen...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full ...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020...
Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including...
Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to ...
Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth ...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast...
Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended...
Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on ...
Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germline genetic tests identify, according to a...
Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors,...
Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide study to better understand the role...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate...
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.